Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome

Véronique M. Braud,Jérôme Biton,Etienne Becht,Samantha Knockaert,Audrey Mansuet-Lupo,Estelle Cosson,Diane Damotte,Marco Alifano,Pierre Validire,Fabienne Anjuère,Isabelle Cremer,Nicolas Girard,Dominique Gossot,Agathe Seguin-Givelet,Marie-Caroline Dieu-Nosjean,Claire Germain
DOI: https://doi.org/10.1080/2162402x.2017.1423184
2018-01-29
OncoImmunology
Abstract:Co-stimulatory and inhibitory receptors expressed by immune cells in the tumor microenvironment modulate the immune response and cancer progression. Their expression and regulation are still not fully characterized and a better understanding of these mechanisms is needed to improve current immunotherapies. Our previous work has identified a novel ligand/receptor pair, LLT1/CD161, that modulates immune responses. Here, we extensively characterize its expression in non-small cell lung cancer (NSCLC). We show that LLT1 expression is restricted to germinal center (GC) B cells within tertiary lymphoid structures (TLS), representing a new hallmark of the presence of active TLS in the tumor microenvironment. CD161-expressing immune cells are found at the vicinity of these structures, with a global enrichment of NSCLC tumors in CD161<sup>+</sup> CD4<sup>+</sup> and CD8<sup>+</sup> T cells as compared to normal distant lung and peripheral blood. CD161<sup>+</sup> CD4<sup>+</sup> T cells are more activated and produce Th1-cytokines at a higher frequency than their matched CD161-negative counterparts. Interestingly, CD161<sup>+</sup> CD4<sup>+</sup> T cells highly express OX40 co-stimulatory receptor, less frequently 4-1BB, and display an activated but not completely exhausted PD-1-positive Tim-3-negative phenotype. Finally, a meta-analysis revealed a positive association of <i>CLEC2D</i> (coding for LLT1) and <i>KLRB1</i> (coding for CD161) gene expression with favorable outcome in NSCLC, independently of the size of T and B cell infiltrates. These data are consistent with a positive impact of LLT1/CD161 on NSCLC patient survival, and make CD161-expressing CD4<sup>+</sup> T cells ideal candidates for efficient anti-tumor recall responses.
oncology,immunology
What problem does this paper attempt to address?